NASDAQ:STOK Stoke Therapeutics Q4 2024 Earnings Results & Report $26.63 -0.05 (-0.19%) Closing price 11/16/2026 04:00 PM EasternExtended Trading$26.63 0.00 (0.00%) As of 11/16/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Stoke Therapeutics beat analyst expectations on both earnings and revenue in its Q4 2024 results, released March 24, 2025. The company reported EPS of -$0.18 versus the -$0.56 consensus estimate, while revenue of $22.61 million topped the $4.20 million estimate by $18.41 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateMarch 24, 2025TimeBefore Market OpensConference Call DateMarch 18, 2025Conference Call7:00 AM ET Stoke Therapeutics EPS ResultsActual EPS-$0.18Consensus EPS -$0.56Beat/MissBeat by +$0.38One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersStoke Therapeutics Revenue ResultsActual Revenue$22.61 millionExpected Revenue$4.20 millionBeat/MissBeat by +$18.41 millionYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Stoke Therapeutics Q4 2024 Earnings FAQ Did Stoke Therapeutics beat earnings estimates for Q4 2024? Stoke Therapeutics (NASDAQ:STOK) reported earnings of -$0.18 per share for Q4 2024, beating the consensus estimate of -$0.56. The report was announced on Monday, March 24, 2025. What was Stoke Therapeutics' revenue for Q4 2024? Stoke Therapeutics reported revenue of $22.61 million for Q4 2024, against a consensus estimate of $4.20 million. Stoke Therapeutics Earnings HeadlinesStoke Therapeutics, Inc. (STOK) - What Are Analysts Thinking About This Stock?November 12, 2026 | americanbankingnews.comStoke Therapeutics (STOK) Faces A Valuation Test Following Weaker Nine Month ResultsNovember 7, 2026 | finance.yahoo.comTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders. | Base Camp Trading (Ad)Equities Analysts Issue Forecasts for STOK FY2026 EarningsNovember 6, 2026 | americanbankingnews.comStoke Therapeutics, Inc. 2026 Q3 - Results - Earnings Call PresentationNovember 3, 2026 | seekingalpha.comStoke Therapeutics, Inc.: Stoke Therapeutics to Present at Upcoming Investor Conferences in NovemberNovember 3, 2026 | finanznachrichten.deSee More Stoke Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Stoke Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Stoke Therapeutics and other key companies, straight to your email. Email Address About Stoke TherapeuticsStoke Therapeutics (NASDAQ:STOK) is a clinical-stage biotechnology company focused on developing genetic medicines for severe diseases caused by insufficient protein production. The company uses its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform to design antisense oligonucleotides that can increase the expression of specific genes and potentially address the underlying causes of genetic disorders. Stoke’s leading product candidate is STK-001, an investigational antisense oligonucleotide being developed for the treatment of Dravet syndrome, a severe genetic epilepsy most commonly associated with mutations in the SCN1A gene. STK-001 is designed to restore productive SCN1A gene expression and increase production of functional sodium channel protein. The candidate has been evaluated in clinical studies involving children and adolescents with Dravet syndrome. Founded in 2014 and headquartered in Bedford, Massachusetts, Stoke conducts research and development activities in the United States and works with clinical and research partners in support of its development programs. The company’s pipeline has also included additional investigational programs aimed at treating rare genetic diseases through targeted increases in gene expression.View Stoke Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/133 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCould Big Buybacks Be the Next Catalyst for These 3 AI Stocks?Cerebras Q3 Results: How Much More Proof Does Wall Street Need? Upcoming Earnings Walt Disney (11/17/2026)Home Depot (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.